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PLASMAPHERESIS IN THE TREATMENT OF MYASTHENIA
GRAVIS
Retrospective study of 26 patients
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ABSTRACT - We analyzed the experience of Unicamp Clinical Hospital with plasma exchange (PE) therapy in myasthenia gravis (MG).
About 17.8 % of a totality of MG patients had PE performed: 26 cases, 19 women and seven men. The mean age-onset of MG was
28 years, extremes 11 and 69. Minimum deficit observed in the group was graded IIb (O & G) or IIIa (MGFA scale). One patient had
prethymectomy PE. In seven the procedures were performed due to myasthenic crisis and in 18 patients due to severe myasthenic
symptoms or exacerbation of previous motor deficit. Two patients were also submitted to chronic PE considering refractoriness to
other treatments. Twenty-six patients had 44 cycles of PE and 171 sessions. The mean number of sessions was 3.9 (SD ± 1.4) each
cycle; median 5, extremes 2 and 6. The mean time by session was 106,5 minutes (SD ± 35.2); median 100.5 (extremes of 55 and
215).The mean volume of plasma exchanged in each session was 2396 ml (SD ± 561); median 2225 (extremes 1512 and 4500). Side
effects occurred: reversible hypotension (seven cases), mild tremor or paresthesias (seven cases). Infection and mortality rates due
to PE were zero.All patients had immediate benefit of each PE cycle and usually they also received prednisone or other immunosup-
pressors. Good acceptance of the procedure was observed in 80.7% of patients.
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Plasmaférese no tratamento da miastenia grave: estudo retrospectivo de 26 pacientes
RESUMO - Analisamos a experiência do Hospital das Clínicas da Unicamp com plasmaferese: (PF) na miastania grave (MG). 17,8
% do total dos casos de MG submeteu-se a PF, 26 casos, 19 mulheres e sete homens. A idade média de início da MG foi 28 anos
(extremos 11 e 69). O menor déficit clínico foi IIb (O & G) e IIIa (MGFA). A PF foi indicada no pré-operatório de timectomia em um
caso e em sete devido a crise miastênica. Em 18 casos, com MG generalizada e sintomas bulbares ou com exacerbação de déficit
prévio, a PF foi indicada como intervenção aguda. Em dois pacientes desse grupo ela foi indicada também em regime crônico de
ciclos mensais. Os 26 pacientes submeteram-se a 44 ciclos e a 171 sessões de PF. O número médio de sessões em cada ciclo foi
3,9 (DP ± 1,4); mediana de 5, extremos 2 e 6. O tempo médio de cada sessão foi 106,5 minutos (DP ± 35,2); mediana de 100,5
(extremos 55 e 215).O volume médio de plasma trocado em cada sessão foi 2396 ml (DP ± 561); mediana 2225 (extremos 1512
e 4500). Efeitos colaterais foram reversíveis: hipotensão (sete casos), tremor ou parestesias leves (sete casos). Taxas de infecção e
mortalidade devido a PF foram zero. A totalidade dos pacientes teve benefícios imediatos a cada ciclo de PF e usualmente rece-
beram prednisona ou outro imunossupressor. Houve boa aceitação ao procedimento em 80,7% dos pacientes.
PALAVRAS-CHAVE: plamaférese, miastenia grave, terapêutica, aceitação, complicações.
Myasthenia gravis (MG) is a well known autoimmune dis-
ease characterized by antibodies against nicotinic acetyl-
choline receptors and fluctuating weakness, sometimes life-
threatening1. Plasmapheresis or plasma exchange (PE) is a ther-
apeutic modality well established in MG2 with a positive re-
commendation based on strong consensus of Class III evidence3.
The two commonest indications for acute PE are myasthenic
crisis and in the preparation for thymectomy3. Chronic PE is a
term to be used when the procedure is performed on a regu-
lar basis4 for a long interval5, and it is proposed for general-
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ized MG refractory to other treatments6.
PE is a therapeutic possibility in seropositive and seroneg-
ative forms of MG7. Its efficiency is due to removal of proteins
of autoimmune biological activity, mainly antibodies to acetyl-
choline receptor8, leading to short-term improvement of neu-
romuscular junction transmission, muscular strength and
motor performance9. Usually, PE is combined with immuno-
suppressive treatment, such as prednisone, azathioprine or
both10,11, to avoid rebound effect and to maintain the improve-
ment12.
We analyzed our experience related to the indications, com-
plications and outcome of PE in MG patients diagnosed and
followed-up at the Neuromuscular Unit. Several aspects of the
procedure itself were also retrospectively reviewed.
METHOD
We reviewed PE protocols of a consecutive series of patients from
the Center of Hemotherapy and charts of MG patients attended at
Unicamp Clinical Hospital. A casuistic of 26 patients was obtained.
They were submitted to a total of 44 cycles and 171 sessions of PE,
during 1993 to January 2002.
Clinical diagnosis of MG was complemented by laboratory exams,
such as repetitive nerve stimulation tests, anti-acetylcholine recep-
tor, anti-striational antibodies and CT images of mediastinum. Patients
were classified according to the Osserman & Genkins (O & G)13 and
MGFA (Myasthenia Gravis Foundation of America)4 scales express-
ing the clinical deficit before PE. Gender, age-onset of MG, level of
serum antibodies, pathological results of the thymus and the disease
status in follow-up were analyzed. Immediate outcome was assessed
shortly after each PE cycle. Overall outcome was based in a follow-
up period comprising the time between the last PE cycle up to January
2002. Patients were classified according to MGFA postintervention
status4.
Continuous-flow cell separators (Dideco Vivacell BT 798 CE/A,
kit 480N400 or Fresenius AS 104, kit PL1) or discontinuous-flow sep-
arator (Haemonetics MCS 3 plus, kit 980/790) machines were
employed. PE was scheduled preferably in an alternate-day intervals
or three consecutive days plus two alternate-days sessions.A periph-
eral vein access was preferred whenever possible or a centrally
placed Shiley’s catheter. Anticoagulation with citrate (ACD formula
A), without heparin, was systematically used. Replacement of plas-
ma removed during PE session was done with isotonic sterile saline,
to make up one-half of the volume and with 4% purified human albu-
min to complete it. Since February 2000, 4% albumin was introduced
earlier in the procedure and for two-thirds of the replacement vol-
ume. A careful monitoring of hemodynamic parameters was provid-
ed and complications during or following PE were rapidly recognized
and reverted by rationale interventions of medical staff that assist-
ed the procedure and the patient. Indications for PE, number of
cycles and sessions, duration of each session, volume of plasma
exchanged and patient tolerance to the procedure were systemati-
cally recorded.We assumed as mandatory to do microbiological cul-
ture of catheter’s extremity when it was removed.
RESULTS
Casuistic included 19 women and seven men; 19 whites
and seven blacks. The mean age-onset of MG was 28 years,
ranges 11 and 69. Clinical classification based on O & G was
IIb (16 cases), III (8 cases) and IV (2 cases). Using MGFA scale
cases were classified as IIIa (8 cases), IIIb (11 cases), IVb (2
cases) and V (5 cases). Eighteen patients were submitted to
thymectomy and the histopathologic diagnosis thymus hyper-
plasia in eight and thymoma in two. In eight patients the
gland was considered normal or exhibiting involution. An
overview of our data may be seen in Table 1.
All patients responded transiently favorable to each cycle
of PE, but none had been exclusively under this therapy.
Prednisone and or azathioprine were the most frequent
immunosuppressors used. PE was indicated due to myas-
thenic crisis in seven patients and for prethymectomy only in
one. Severe motor dysfunction, especially related to bulbar signs
or exacerbation of myasthenic weakness associated with cor-
ticosteroids indicated PE in 18 patients.Two patients were sub-
mitted to 6 and 5 cycles of PE respectively. A monthly sched-
ule of two consecutive-days sessions was used and the max-
imum motor improvement varied from two to four weeks.
Twenty-six patients had 44 cycles of PE and a total 171
sessions. The mean number of PE sessions was 3.9 (SD ±1.4)
each cycle; median of 5 (ranges 2 and 6). The mean time of
each session was 106.5 minutes (SD ± 35.2); median 100.5
(ranges 55 and 215). The mean volume of plasma exchanged
was 2396 ml (SD ± 561); median 2225, ranges 1512 and
4500. Side effects were mild and citrate dependent in seven
patients. Hypotension occurred in seven cases. No catheter plac-
ing problems or infection were observed and no death occurred
in consequence of PE. Good PE acceptance occurred in 80.7
% of cases.
Each cycle of PE resulted in immediate improvement of clin-
ical status in every patient of the series. However, after the mean
follow-up of 24 months (median 14.5; ranges 1 month and 8
years and 5 months), clinical status was recorded as complete
stable remission (CSR) in five patients; pharmacological remis-
sion (PR) in two; minimal manifestations, taking low-dose of
cholinesterase inhibitors (MM2) in five; minimal manifestations,
with low-dose cholinesterase inhibitors and some immunosup-
pressor (MM3) in three; substantial decrease in clinical man-
ifestations and reduction in medications (I) in eight; no sub-
stantial change in pretreatment clinical manifestations (U) in
two. Death was registered once, but it was not directly relat-
ed to PE.
DISCUSSION
PE was firstly described as a therapeutic procedure for MG
in 1976 by Pinching and Peters14. During 1981-97 the disease
was between the five most frequent indications for PE in
Canada, but the second in 199715. A multicenter study from
Taiwan showed that 34.9% of PE was indicated for MG
patient16. A restricted number of national publications about
PE and MG was encountered17-20. Seggia et al.17 from Rio de
Janeiro analyzed costs and benefits of PE in the preparation
of patients for thymectomy.
The first MG patient submitted to PE at Unicamp Clinical
Hospital was in 1993 and the present PE series includes about
17.8 % of all MG patients followed-up at the Institution from
1982 to January 2002.The proportion of 2.7:1 for female:male
and the demographic characteristics of the group represent
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the populations attended and the most severely diseased.
Clinical manifestations of MG were recorded according to O
& G scale13 as IIb (moderate generalized with bulbar signs) in
16 cases, III (acute fulminating) in eight cases, IV (late severe)
in two cases. Regarding to MGFA scale4, patients were clas-
sified as class IIIa (moderate weakness predominantly affect-
Table 1. Summary of data from the casuistic.
Case Gender Race MG age- O & G MGFA Anti- Striational Thymus Cycles Sessions Follow-up
onset (y) AChR antibodies gland
1 F W 28 II b III b Normal 1 5 CSR 1y 3m
2 M B 30 II b III a 14,5* neg Hyperplasia 1 5
6 2 U 8m
3 M W 26 II b III b 145 1/640 Thymoma 1 5 PR 2y 3m
4 M W 21 II b III a Hyperplasia 1 5 CSR 1y 8m
5 F W 28 III V 0.13 Thymoma 1 4 PR 4y 4m
6 F W 28 II b III a Normal 1 2 MM2 1y 6m
7 F W 38 II b III a Neg 1 5 U 1y 10m
8 M B 25 IV IV b Normal 1 5 I 1y 2m
9 M W 46 II b III a Normal 1 5 I 1y 4m
10 F W 38 II b III b 1 5 I 1y 2m
11 F W 22 II b III b 1.92 Hyperplasia 1 5 CSR 1y 2 m
12 F W 19 II b III b 0.05 Hyperplasia 2 5 I 1m
13 F B 21 IV V 4.49* Normal 1 5 DEATH * 5m
14 F W 23 II b III a 11.5 1 5 I 6m
15 F B 35 III V Normal 1 3 MM2 7y 3m
16 F W 31 II b III a Hyperplasia 1 5 CSR 13m
17 F B 34 II b III b 1 5 I 8m
18 M W 69 II b III b 8.53 1/160 1 5 MM2 7y 5m
19 F W 28 II b III b 1 4
1 5 I 2m
20 F W 26 II b III a 50.6 1 3 MM3 1y 11m
21 F W 21 III V 0.62 Hyperplasia 1 4 CSR 5y 6m
22 F W 24 III V 15.7 Normal 1 6
1 2
1 4 MM2 2y 9m
23 F W 43 III III b 1 3 MM3 1m
24 M B 14 III III b Normal 3 5
1 4
5 2 I 1y 7m
25 F W 14 III III b 144 Hyperplasia 1 5 MM3 1y 1m
26 F B 11 III IV b Hyperplasia 1 5 MM2 1y 2m
F, female; M, male; B, black; W, white; (y), years; For O & G = MGFA and abbreviations related with follow-up, see text; Anti-AChR, anti-acetylcholine receptor binding antibod-
ies; reference values ≤ 0,02 nmol/L. *reference values < 0.8 nmol/L.; neg = negative; * death occurred 6 years and 3 months after thymectomy and 5 months after PE 
ing limb, axial muscle or both and lesser involvement of
oropharyngeal muscles) in eight cases; IIIb (deficit predomi-
nantly oropharyngeal and/or respiratory plus limb and/or axi-
al muscles lesser involved) in 11 cases; IVb (severe weakness
predominantly affecting oropharyngeal and/or respiratory
muscles, may also have lesser or equal deficit of limb, axial
muscles or both) in two and class V (intubated, with or with-
out mechanical ventilation) in five cases. The least severe
grade of the disease for which we indicated PE was IIb accord-
ing to O & G, corresponding to IIIa in the MGFA scale. PE was
indicated due to myasthenic crisis in seven cases, 26.9 % of
the casuistic. Werneck et al.20 used PE as specific treatment
in 16.6 % of 24 cases of these potentially fatal condition.
In case 6 PE was performed four days previous to thymec-
tomy for preparing the patient to surgery, as suggested by oth-
ers17,21,22 .The patient had difficulty in the maintenance of motor
strength while lowering prednisone. As expected postopera-
tive result was uneventful. Dias-Tosta and Fernandes18 report-
ed eight patients submitted to PE: five indicated as prethymec-
tomy in cases with restricted vital capacity and in three cas-
es the procedure was performed after surgery because wors-
ening of motor power.
In 18 cases PE was indicated because severe motor deficit,
especially bulbar dysfunction or due to exacerbation of deficit
induced by corticosteroid. This drug is the first choice in the
therapy of MG, regarding the autoimmune aspects of the dis-
ease, but half of the patients may worsen, requiring careful
monitoring1.
Cases 2 and 24 were submitted to PE also because other
therapies failed to achieve the necessary sustained motor per-
formance for daily life activities. They had 6 and 5 cycles of
PE respectively, in a monthly schedule of two consecutive
days sessions. Chronic PE was proposed by Kornfeld et al.6 as
effective therapy in cases of generalized MG refractory to
other treatments. Rodnitzky and Bosch5 described two cases
of intermittent PE therapy prescribed up to five years without
significant side effects.
Korach et al.23 observed that immediate complications of
PE decreased by half in the last 15 years according to the French
PE registry. Anticoagulation with sodium citrate solution was
responsible for 3% of side effects in all PE procedures24, like
perioral tingling, trembling, dizziness and hypotension24,25.
Hypocalcemia resulted in mild paresthesias and tremor in sev-
en of our patients.Vasovagal attack with concomitant hypoten-
sion, true hypovolemia or fluid overload may also be compli-
cations of PE25. Hypotension occurred in seven of our 26
patients and was  reversed by fluid replacement. In a group
of 144 sessions of PE,Wendell Neto et al.19 encountered 10.4
% of paresthesias, 2 % of hypotension and 10,4 % of aller-
gic reactions. Seggia et al.17 also presented a list of PE side effects
in their patients, all easily managed.
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Placement of the central catheter can be the cause of
major complications associated with PE, such as pneumoth-
orax, thrombosis or infection 24,25. Microbiological culture of
catheter’s extremity was always negative in our patients. In
our series there was no death directly related to PE. In case
13, the patient was a chronic ventilator dependent with
diaphragmatic paralysis. She had a prolonged hospitalization,
evolving to death from sepsis that occurred five months after
PE. Kiprov et al.24 found a mortality rate of 0.006% from two
large mobile apheresis services. In a survey of seven years PE
in Mexico, the mortality rate was 0.2% 26.
In conclusion, acute PE was a rational treatment for patients
with myasthenic crisis and in preparation for thymectomy. It
had a favorable short-term impact on severe weakness and
exacerbation of symptoms. PE was used in association with
prednisone or other immunosuppressor while waiting for fur-
ther stable improvement or disease remission. On a chronic
intermittent basis, PE was indicated for patients who had pre-
viously failed to respond to other therapies. In our cases imme-
diate improvement in motor performance was detected, either
by a reduction of deficit or a diminution of daily doses of
cholinesterase inhibitors and of immunosuppressive drugs.
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